<DOC>
	<DOCNO>NCT00715702</DOCNO>
	<brief_summary>The purpose study investigate pharmacokinetics single dose AZD5672 patient renal impairment compare healthy volunteer</brief_summary>
	<brief_title>Safety Study AZD5672 Renally Impaired Subjects</brief_title>
	<detailed_description />
	<mesh_term>Renal Insufficiency</mesh_term>
	<mesh_term>N- ( 1- ( 3- ( 3,5-difluorophenyl ) -3- ( 4-methanesulfonylphenyl ) propyl ) piperidin-4-yl ) -N-ethyl-2- ( 4-methanesulfonylphenyl ) acetamide</mesh_term>
	<criteria>Provision sign write informed consent . Females childbearing potential Subjects classify renally impaired stable ( Investigator 's opinion ) least 3 month prior Visit 1 . Patients take prescription medication : Pgp substrates , inhibitor /or inducer , medication affect creatinine clearance ( within 7 day dose ) , atorvastatin &gt; 20mg daily , medication prolong QT/QTc interval Change dose regimen prescribe medication NSAIDs within 2 week enrolment ( renal patient ) Participation another clinical study involve administration investigational product 3 month prior treatment ( within 5 halflives last dose investigational product , whichever long )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2009</verification_date>
	<keyword>AZD5672</keyword>
</DOC>